These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 35834275)
1. Urinary serpin-A3 is an early predictor of clinical response to therapy in patients with proliferative lupus nephritis. Martínez-Rojas MÁ; Sánchez-Navarro A; Mejia-Vilet JM; Pérez-Villalva R; Uribe N; Bobadilla NA Am J Physiol Renal Physiol; 2022 Oct; 323(4):F425-F434. PubMed ID: 35834275 [TBL] [Abstract][Full Text] [Related]
2. The first-year course of urine MCP-1 and its association with response to treatment and long-term kidney prognosis in lupus nephritis. Pérez-Arias AA; Méndez-Pérez RA; Cruz C; Zavala-Miranda MF; Romero-Diaz J; Márquez-Macedo SE; Comunidad-Bonilla RA; García-Rueda CC; Mejía-Vilet JM Clin Rheumatol; 2023 Jan; 42(1):83-92. PubMed ID: 36107264 [TBL] [Abstract][Full Text] [Related]
3. Association of Urinary Matrix Metalloproteinase 7 Levels With Incident Renal Flare in Lupus Nephritis. Wang G; Wu L; Su H; Feng X; Shi M; Jin L; Yang M; Zhou Z; Su C; Yang B; Li Y; Cao W Arthritis Rheumatol; 2021 Feb; 73(2):265-275. PubMed ID: 32892475 [TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes in refractory lupus nephritis: Data from an observational study. Gururani S; Devarasetti PK; Uppin M; Rajasekhar L Lupus; 2021 Oct; 30(11):1725-1731. PubMed ID: 34304627 [TBL] [Abstract][Full Text] [Related]
5. Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis. Whittall-Garcia L; Goliad K; Kim M; Bonilla D; Gladman D; Urowitz M; Fortin PR; Atenafu EG; Touma Z; Wither J Front Immunol; 2022; 13():889931. PubMed ID: 35711439 [TBL] [Abstract][Full Text] [Related]
6. The influence of repeated flares in response to therapy and prognosis in lupus nephritis. Perez-Arias AA; Márquez-Macedo SE; Pena-Vizcarra OR; Zavala-Miranda MF; Romero-Díaz J; Morales-Buenrostro LE; Mejía-Vilet JM Nephrol Dial Transplant; 2023 Mar; 38(4):884-893. PubMed ID: 36318456 [TBL] [Abstract][Full Text] [Related]
7. Urinary high-mobility group box-1 associates specifically with lupus nephritis class V. Jog NR; Blanco I; Lee I; Putterman C; Caricchio R Lupus; 2016 Dec; 25(14):1551-1557. PubMed ID: 27075010 [TBL] [Abstract][Full Text] [Related]
8. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. De Rosa M; Azzato F; Toblli JE; De Rosa G; Fuentes F; Nagaraja HN; Nash R; Rovin BH Kidney Int; 2018 Oct; 94(4):788-794. PubMed ID: 30045812 [TBL] [Abstract][Full Text] [Related]
9. Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis. Yu KY; Yung S; Chau MK; Tang CS; Yap DY; Tang AH; Ying SK; Lee CK; Chan TM Lupus; 2021 Jun; 30(7):1039-1050. PubMed ID: 33765901 [TBL] [Abstract][Full Text] [Related]
12. Serum level of proximal renal tubular epithelial cell-binding immunoglobulin G in patients with lupus nephritis. Yap DY; Yung S; Zhang Q; Tang C; Chan TM Lupus; 2016 Jan; 25(1):46-53. PubMed ID: 26251400 [TBL] [Abstract][Full Text] [Related]
13. Urinary free light chain is a potential biomarker for ISN/RPS class III/IV lupus nephritis. Hanaoka M; Gono T; Kawaguchi Y; Uchida K; Koseki Y; Katsumata Y; Kaneko H; Takagi K; Ichida H; Nitta K; Yamanaka H Rheumatology (Oxford); 2013 Dec; 52(12):2149-57. PubMed ID: 23463805 [TBL] [Abstract][Full Text] [Related]
14. Impact of stringent response in proteinuria on long-term renal outcomes in proliferative lupus nephritis. Won J; Lee JS; Oh JS; Kim YG; Lee CK; Yoo B; Hong S Lupus; 2019 Oct; 28(11):1294-1301. PubMed ID: 31583978 [TBL] [Abstract][Full Text] [Related]
15. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Avihingsanon Y; Phumesin P; Benjachat T; Akkasilpa S; Kittikowit V; Praditpornsilpa K; Wongpiyabavorn J; Eiam-Ong S; Hemachudha T; Tungsanga K; Hirankarn N Kidney Int; 2006 Feb; 69(4):747-53. PubMed ID: 16518330 [TBL] [Abstract][Full Text] [Related]
16. Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. Gilbert M; Goilav B; Hsu JJ; Nietert PJ; Meidan E; Chua A; Ardoin SP; Wenderfer SE; von Scheven E; Ruth NM; Pediatr Rheumatol Online J; 2021 Aug; 19(1):137. PubMed ID: 34461932 [TBL] [Abstract][Full Text] [Related]
17. Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis. Parodis I; Ding H; Zickert A; Cosson G; Fathima M; Grönwall C; Mohan C; Gunnarsson I PLoS One; 2019; 14(2):e0212068. PubMed ID: 30742665 [TBL] [Abstract][Full Text] [Related]
18. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Malvar A; Alberton V; Lococo B; Ferrari M; Delgado P; Nagaraja HN; Rovin BH Kidney Int; 2020 Jan; 97(1):156-162. PubMed ID: 31685314 [TBL] [Abstract][Full Text] [Related]
19. Urinary Angiotensinogen Predicts Renal Disease Activity in Lupus Nephritis. Shi M; Luo W; Feng X; Jin L; Yang M; Wu L; Yang Z; Su C; Li Y; Su H; Wang G; Cao W Antioxid Redox Signal; 2019 Dec; 31(17):1289-1301. PubMed ID: 31264479 [No Abstract] [Full Text] [Related]